PRIMA EU Retrospective & Prospective

This clinical study aims at evaluating clinical, radiographic and patient-reported outcomes after total anatomic or reverse shoulder replacement using PRIMA humeral stem up to 24 months after surgery, in order to assess the short-term performance of the implant. Furthermore, the objective is also to collect short-term data on the survivorship of the implant and the incidence of complications.

Inclusion Criteria: 1. Age ≥ 18 years old; 2. Full skeletal maturity; 3. Life expectancy over 24 months; 4. Patient's joint anatomically and structurally suited to receive the selected implants and functional deltoid muscle; 5. Patient meets at least one of the following indications: For Anatomic configuration: * non-inflammatory degenerative joint disease (i.e., osteoarthritis); * inflammatory arthritis of the glenohumeral joint including rheumatoid arthritis; * avascular necrosis of the humeral head; * cuff tear arthropathy (CTA Heads only); For Reverse configuration: * rotator cuff tear arthropathy; * osteoarthritiswith rotator cuff tear; * rheumatoid arthritis with rotator cuff tear; * massive irreparable rotator cuff tear; 6. Patient is able to understand the conditions of the study, to comply with the prescribed rehabilitation as well as willing to perform all scheduled follow-up visits; 7. Patient has signed the Informed Consent form previously approved by the Ethics Committee before study activities. Exclusion Criteria: 1. Patients who lack capacity to be able to provide informed consent to participate in the study. 2. Local or systemic general infection; 3. Septicaemia; 4. Persistent acute or chronic local or systemic osteomyelitis; 5. Confirmed neurologic lesion compromising shoulder joint function; 6. Deltoid muscle insufficiency; 7. Poor meta-epiphyseal bone stock compromising stability of the implant (severe fracture of the proximal humerus, meta-epiphyseal pseudoarthrosis, osteoporosis, osteomalacia, extended bone loss after previous prosthetic or non-prosthetic surgery); 8. Affected by malignant cancer with life expectancy less than 2 years or where cancer treatment might affect the normal postoperative course; 9. Serious muscular, neurological, or arterial vascular diseases compromising stability of the implant; 10. Proximal humerus fracture sequelae with inadequate bone stock; 11. Vascular or nerve diseases affecting the concerned limb; 12. Metabolic disorders which may impair fixation and stability of the implant; 13. Any concomitant disease that might affect the implanted prosthesis; 14. Metal hypersensitivity to implant materials (CoCrMo); 15. Patient with significant renal impairment; 16. Lower mobility issues that may affect the study evaluation; 17. Unwillingness or inability (due to physical or mental issues) to comply with rehabilitation and to return for follow-up visits and any psychiatric illness that would prevent comprehension of the details and nature of the study; 18. Women of childbearing potential who are pregnant, nursing, or planning to become pregnant; 19. Any clinically significant pathology based on the medical history that the Investigator feels may affect the study evaluation.